CVS Health (CVS), headquartered in Woonsocket, Rhode Island, generated $402 billion in revenue in fiscal year 2025 across three operating segments: a pharmacy benefit manager, a health insurer, and a chain of approximately 9,000 retail pharmacies. Layered on top of those is an $18+ billion bet on primary care clinics and in-home health assessments that has not yet produced the returns management projected. The company carries $63.7 billion in total debt, reported GAAP net income of just $1.77 billion after a $5.7 billion goodwill impairment and $1.5 billion in litigation charges, and trades at $76.13 as of this writing. This post breaks down each segment, the logic and execution of the integration strategy, and the key variables that will determine whether CVS is a recovery story or a value trap.
The Integration Thesis
CVS spent most of the last decade building toward a specific vision: control every financially significant layer of the patient journey. You get insurance through Aetna. Your prescriptions are managed by CVS Caremark, the PBM. You fill them at a CVS pharmacy. Your primary care physician works at an Oak Street Health clinic, focused on Medicare patients in a value-based care model. A Signify Health clinician visits your home to catch chronic conditions early and feed risk adjustment data back into the system.
The strategic logic is coherent. Each individual layer of the healthcare business is commoditized and under pressure. PBMs face political scrutiny. Retail pharmacy margins are thin and shrinking. Health insurance is a low-margin volume game susceptible to medical cost spikes. But if CVS can demonstrate that owning all three layers produces better clinical outcomes and lower total cost of care for members, the integrated model creates a moat that a single-layer competitor cannot replicate.
The assembly of this model cost a significant amount of money. CVS acquired Aetna in 2018 for $69 billion, one of the largest healthcare deals in history. It acquired Signify Health in 2023 for $8 billion to build out in-home health evaluations. It acquired Oak Street Health in 2023 for $10.6 billion to establish value-based primary care clinics for Medicare patients. The total acquisition spend on these three deals alone is roughly $88 billion, financed largely with debt. Integration costs, ongoing capital expenditures, and operating losses at the newer businesses add to the total.
The 2025 10-K includes a $5.7 billion goodwill impairment on the Health Care Delivery unit, which houses Oak Street. That is the clearest possible signal that management overpaid or overestimated the pace of growth, or both. CVS is now slowing Oak Street clinic openings and closing underperformers. A company that has found a working formula does not behave that way.
Segment 1: Health Services (The PBM)
What It Is
Health Services is the CVS Caremark pharmacy benefit management business, plus the healthcare delivery assets (Oak Street and Signify). In fiscal year 2025, it generated $190 billion in revenues and $7.15 billion in adjusted operating income.
The PBM is the core. CVS Caremark manages pharmacy benefits for 87 million plan members and processed 1.9 billion prescriptions in 2025. A PBM sits between employers, health insurers, and government programs on one side and drug manufacturers and pharmacies on the other. The PBM negotiates drug prices with manufacturers, builds formularies (lists of covered drugs), processes claims, and manages the pharmacy network. The model generates revenue through administrative fees, spread pricing (charging the payer more than it reimburses the pharmacy), and rebates from manufacturers.
The PBM is not a glamorous business, but it is durable. Health Services has produced adjusted operating income between $7.1 billion and $7.3 billion for three consecutive years. That kind of consistency at that scale is worth paying attention to. The low margin (~4%) on $190 billion in revenue is structural, not a problem. Volume is the point.
What to Worry About
The political risk here is real and ongoing. PBMs have been under sustained scrutiny from Congress for their role in drug pricing. The core criticism is that PBMs profit by keeping drug prices high, since their rebates from manufacturers are larger on expensive drugs. CVS disputes this characterization, and management has argued that recent PBM legislation is actually an accelerant for its TrueCost transparent pricing model rather than a threat – the argument being that regulation pushes the market toward the pass-through model CVS has already been building. That is a credible counterargument, but it assumes the legislative outcome aligns with what CVS has already built, which is not guaranteed.
State legislatures have passed or are considering laws that would prohibit pharmacies affiliated with a PBM from operating in certain markets, which is a direct threat to CVS’s integrated model. Arkansas, Louisiana, North Dakota, and Oklahoma have all attempted to limit PBM practices and have been the subject of litigation. The 10-K is direct about the risk: “We may face increased regulatory risks related to our vertical integration strategy, such as legislation prohibiting state licensure of pharmacies affiliated with a PBM.”
The spread pricing model is also under pressure. Clients are increasingly demanding that PBMs pass through more of the manufacturer rebates, which compresses margins. CVS has been managing this, but it is a structural headwind.
A newer threat worth watching is the direct-to-consumer pharmaceutical trend. Drug manufacturers are increasingly building their own DTC platforms, bypassing the PBM and pharmacy entirely for certain high-demand products. If this model takes hold at scale for any major drug category, it removes volume from both the PBM and the pharmacy simultaneously.
Oak Street and Signify: The Expensive Add-Ons
Oak Street and Signify sit inside Health Services, which complicates the segment’s financials. The PBM alone is a cash machine. The healthcare delivery businesses are still burning capital.
Oak Street is a network of primary care clinics focused on Medicare Advantage patients in a value-based care model. The concept is straightforward: if you provide excellent primary care to seniors, they visit the emergency room less, get hospitalized less, and cost the health plan less. Oak Street contracts with health plans on a capitated basis, taking on risk for the total cost of care for its patients.
The problem is execution and scale. Building a primary care clinic network requires recruiting physicians, building or leasing facilities, establishing relationships with health plans, and enrolling patients. All of this takes years. CVS paid $10.6 billion for the business, and then wrote off $5.7 billion of that acquisition cost in 2025 because the growth trajectory did not meet projections. Management is now slowing clinic openings and closing underperformers. The number of Oak Street medical centers in operation fell over the course of 2025.
Signify Health performs in-home health evaluations for Medicare Advantage members. The value proposition is that home visits allow clinicians to catch conditions that do not show up in office visits, which improves risk adjustment accuracy and closes care gaps. CVS paid $8 billion for Signify, and the integration is still ongoing.
Both businesses are strategically logical. Neither has yet demonstrated the unit economics that would justify the purchase prices paid.
Segment 2: Health Care Benefits (Aetna)
What It Is
Health Care Benefits is the Aetna insurance business, which CVS acquired in 2018. It covers roughly 26.6 million medical members across Medicare Advantage, commercial insurance, and Medicaid, plus additional members in dental, vision, and other ancillary products. In fiscal year 2025, it generated $143 billion in revenues and $2.94 billion in adjusted operating income.
The primary financial metric for an insurer is the medical benefit ratio (MBR): the percentage of premium revenue paid out in medical claims. A lower MBR means more of each premium dollar flows to operating income. An MBR above roughly 90% means the insurer is keeping less than 10 cents on every dollar of premium after claims, before administrative costs and taxes.
Aetna has spent three years demonstrating how volatile this business can be:
| Year | Adj. Operating Income | MBR |
|---|---|---|
| 2023 | $5.6B | 86.2% |
| 2024 | $307M | 92.5% |
| 2025 | $2.94B | 91.2% |
In 2024, adjusted operating income fell from $5.6 billion to $307 million. Medical costs came in significantly above what Aetna had priced into its plans. Insurance companies price products months in advance based on projected utilization. If actual utilization exceeds projections – and in 2024, driven by elevated use of outpatient services and post-COVID behavioral health claims – the company absorbs the difference. Aetna could not raise prices fast enough to catch up. The MBR moved six percentage points in a single year, and $5.3 billion in operating income disappeared.
The 2025 recovery is real, but partial. Adjusted operating income recovered to $2.94 billion, but that is still roughly half of what Aetna earned in 2023. The MBR improved from 92.5% to 91.2%, moving in the right direction but still elevated compared to the 2023 baseline.
There were also two premium deficiency reserves recorded in 2025: a $448 million reserve on the individual exchange product line in Q1, and a $471 million reserve on the Group Medicare Advantage product line in Q2. A premium deficiency reserve means the company determined that premiums already collected would be insufficient to cover expected claims for the rest of the year. CVS subsequently exited the ACA public exchanges entirely, effective January 2026.
Medicare Advantage Specifics
Medicare Advantage is the largest and most strategically important product line within Health Care Benefits, and it has its own set of complications.
The business depends on star ratings from CMS, the federal agency that administers Medicare. Plans rated four stars or higher receive a quality bonus in their payment rates from the government. CVS reported that more than 81% of its Medicare Advantage members were in four-star or higher plans for 2026, and more than 63% were in 4.5-star plans. That is a reasonably strong position, but CMS regularly changes its rating methodology to make high ratings harder to achieve.
The 2027 Medicare Advantage rate announcement, issued as an advance notice in January 2026, proposed an average revenue increase of 2.54% for the industry. Without including risk score adjustments, the underlying rate increase is just 0.09% – essentially flat, against a backdrop of medical cost inflation running meaningfully higher. CVS CEO David Joyner was direct on the Q4 2025 earnings call: “The proposed rate simply does not match the level of medical cost trend in the industry.” CVS will need to either raise premiums, reduce benefits, or accept margin compression in its Medicare Advantage business in 2027. Management stated its commitment to Aetna margin recovery is unchanged despite the rate environment, but the math of flat rates against elevated trend is a real constraint.
CMS also announced in May 2025 that it would audit every Medicare Advantage contract for each payment year, with an expedited plan to complete audits for payment years 2018 through 2024 by early 2026. This is a meaningful risk. If audits result in retroactive adjustments to risk adjustment payments, CVS could face material refunds to the government.
The Competitive Threat
Aetna competes against UnitedHealth Group, Humana, Elevance Health, and a dozen regional insurers for every member it serves. In Medicare Advantage specifically, United and Humana have larger market shares and, in recent years, have generally managed their MBRs more tightly. Aetna’s 2024 performance underperformed peers, which damages its competitive positioning in future enrollment cycles.
Segment 3: Pharmacy and Consumer Wellness (Retail)
What It Is
Pharmacy and Consumer Wellness is the retail business: approximately 9,000 stores across the United States dispensing prescriptions and selling front-store consumer products. In fiscal year 2025, it generated $139 billion in revenues and $6.04 billion in adjusted operating income.
This is what most people think of when they think of CVS: a pharmacy with a retail store attached. The business is much larger than that description implies, but the fundamentals are accurate.
Pharmacy same-store sales grew 18% in 2025. That is an exceptional number, and it is driven primarily by two factors: the Rite Aid prescription file acquisitions, which brought 9 million new patients into CVS locations after Rite Aid’s bankruptcy left communities without a local pharmacy option, and the ongoing surge in branded GLP-1 medications for diabetes and obesity management (Ozempic, Wegovy, Mounjaro, and related drugs). GLP-1 drugs are among the most expensive branded medications dispensed by volume, and they are being prescribed at a rapidly increasing rate.
The GLP-1 tailwind is real, but it requires some nuance. These drugs are expensive, which inflates revenue per prescription. The margin on branded drugs is generally lower than on generic substitutes. And if GLP-1 drugs eventually face biosimilar competition – which is coming, though the timing is uncertain – revenue and margin dynamics could shift significantly.
The Front Store Problem
The non-pharmacy portion of CVS stores – the retail products, seasonal merchandise, personal care items, and over-the-counter drugs – is in a slow structural decline. As a share of segment revenue, front store has been shrinking for years:
| Year | Front Store % of Segment Revenue |
|---|---|
| 2023 | ~21% |
| 2024 | ~19% |
| 2025 | ~17% |
The reasons are straightforward. Amazon and mass retailers like Walmart and Target offer the same products at competitive prices with the convenience of home delivery. The CVS front store was already structurally challenged before e-commerce matured, and the trend has continued. CVS has been reducing front-store SKUs, closing underperforming locations, and leaning into health-oriented merchandise, but the mix shift is ongoing.
The pharmacy remains the anchor. Prescription volume is largely sticky – patients with chronic conditions and established relationships with their pharmacist tend not to switch unless the insurance coverage changes or a competitor is dramatically more convenient. The front store is an increasingly difficult attachment sale.
Store Count Trajectory
CVS has been actively managing its store count, closing underperforming locations. The company closed approximately 900 stores over the 2022-2025 period as part of a restructuring effort. There are still roughly 9,000 locations as of year-end 2025, but the number continues to trend down gradually. Management views this as a rationalization, not a retreat, but it is worth tracking.
The Financials: What Actually Matters
Segment Summary
| Segment | 2025 Revenue | 2025 Adj. Operating Income |
|---|---|---|
| Health Services (PBM + delivery) | $190.0B | $7.15B |
| Health Care Benefits (Aetna) | $143.3B | $2.94B |
| Pharmacy & Consumer Wellness | $139.3B | $6.04B |
| Intersegment Eliminations | ($71.6B) | – |
| Corporate / Other | $0.5B | ($1.69B) |
| Consolidated | $402.0B | $14.44B |
The intersegment eliminations represent transactions between CVS businesses – Aetna members filling prescriptions at CVS pharmacies, Caremark managing prescriptions for Aetna plans. The integration thesis is visible in that $71.6 billion figure. Whether it is generating incremental value above what each business would produce independently is harder to measure.
Cash Flow and Capital Allocation
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Operating Cash Flow | $13.4B | $9.1B | $10.6B |
| Capital Expenditures | ($3.0B) | ($2.8B) | ($2.8B) |
| Free Cash Flow | $10.4B | $6.3B | $7.8B |
| Dividends Paid | $3.1B | $3.4B | $3.4B |
| Dividend % of FCF | 30% | 53% | 44% |
| Share Repurchases | – | – | – |
Management has stated that debt reduction is a priority. The math tells a more complicated story. Total debt sits at $63.7 billion, costing $3.1 billion per year in interest, and the leverage ratio at year-end 2025 was approximately 4x. After the dividend and capital expenditures, the remaining FCF available for debt paydown is roughly $1.6 billion per year at 2025 cash flow levels. Against a $63.7 billion debt load, that is a negligible dent.
The dividend is the constraint. CVS pays $2.66 per share annually, held flat since 2024 with no raise. Management has signaled clearly that the dividend is not going away, and at a 44% FCF payout ratio it is well-covered at 2025 earnings levels. But the consequence of protecting the dividend is that organic debt reduction is nearly impossible. The actual path to a materially lower debt load is Aetna’s earnings recovery, not balance sheet discipline. If Aetna returns toward its 2023 profitability levels, operating cash flow expands, the payout ratio compresses, and meaningful deleveraging becomes possible. If Aetna stumbles again, the math gets worse, not better.
One additional wrinkle: management guided 2026 operating cash flow to at least $9 billion, down from $10.6 billion in 2025. The decline reflects payments that shifted from 2026 into late 2025. If 2026 OCF comes in at $9 billion and capex holds at $2.8 billion, FCF drops to roughly $6.2 billion and the dividend consumes closer to 55% of it – back toward the uncomfortable 2024 range.
Credit agencies carry negative outlooks on CVS at investment grade ratings from both S&P and Fitch. Moody’s rates CVS at Baa3 with a Stable outlook. A downgrade from investment grade would increase borrowing costs and potentially trigger covenant issues across portions of the debt structure. The company has limited room to absorb another bad insurance year before the credit picture deteriorates.
The Goodwill and Litigation Overhang
GAAP net income of $1.77 billion in 2025 reflects two large non-recurring items:
Goodwill impairment: $5.7 billion. This is a non-cash charge, but it is not meaningless. It represents CVS acknowledging that the fair value of the Health Care Delivery unit is $5.7 billion less than what it paid. The remaining goodwill and intangible asset balance on the balance sheet is still substantial, and the 10-K includes explicit language warning that further impairments are possible if performance does not improve.
Litigation charges: ~$1.5 billion. This breaks down into approximately $1.2 billion related to an Omnicare False Claims Act verdict and a PBM DIR reporting practices case, and approximately $320 million in opioid litigation charges. CVS has been a defendant in hundreds of opioid-related proceedings. The Omnicare matter relates to alleged improper claims in the long-term care pharmacy business. These are not one-time events in the sense that the litigation pipeline continues.
The Key Risks
Several of the risks disclosed in the 10-K are worth flagging specifically, because they are not boilerplate.
Medical cost forecasting is structurally uncertain. Aetna prices its insurance products months in advance based on projected utilization. During periods of rapidly changing medical cost trends – post-COVID utilization normalization, GLP-1 adoption, behavioral health demand – the gap between projected and actual costs can be significant. The 2024 experience is the proof of concept for how badly this can go.
Government program dependency. A substantial portion of CVS revenue flows from Medicare, Medicare Part D, and Medicaid. Changes in CMS payment rates, star rating requirements, or audit findings can move meaningful amounts of money. The proposed 2027 Medicare Advantage rates, if finalized essentially flat, will create margin pressure in a part of the business that is already recovering from 2024.
Vertical integration regulatory risk. CVS is large enough, and spans enough of the healthcare value chain, that it draws regulatory scrutiny. State laws targeting PBM-affiliated pharmacies are an early expression of this. The 10-K is explicit: as CVS executes its integration strategy, “litigation is increasing.” The company is both the integrator and the target.
Tariff exposure in pharmaceuticals. Much of the branded and generic drug product CVS sells is manufactured outside the United States. The current administration has imposed and may further impose tariffs on imported products. CVS acknowledges this directly: “significant changes in tax or trade policies, tariffs or trade relations between the U.S. and other countries… could result in significant increases in our costs.” This is a newer risk that was not material in prior years.
Goodwill impairment is not over. The 10-K includes specific language warning that goodwill and intangible assets could become impaired in the future. The remaining goodwill balance across all segments is still large. If Aetna fails to continue its MBR recovery, another impairment is possible.
What Has to Go Right
CVS is priced at roughly 5x adjusted operating income at the current stock price. That is a low multiple for a company generating $14 billion in adjusted operating income, and it reflects the market’s skepticism about whether that number is sustainable.
Three things have to go right simultaneously for the stock to re-rate meaningfully.
Aetna has to continue recovering. The MBR improved from 92.5% to 91.2% in 2025. Getting back toward the 86-87% range that produced $5.6 billion in adjusted operating income would add $2-3 billion to annual earnings. That is the biggest single lever in the model. One more bad medical cost year ends the recovery thesis.
Oak Street has to find its unit economics. The $5.7 billion impairment was a significant admission. CVS needs Oak Street to demonstrate that at some reasonable scale, value-based primary care reduces Medicare Advantage costs enough to justify the capital invested. If Oak Street continues to underperform, there could be further writedowns, and the healthcare delivery thesis falls apart entirely.
The PBM has to survive regulation. CVS Caremark’s $7 billion-plus in annual adjusted operating income is the engine that funds everything else. Adverse legislative or regulatory action that materially changes how PBMs operate or how much they can earn would hollow out the center of the model.
If all three go reasonably well, CVS is a company with durable cash generation, a manageable dividend, and a credible path to debt reduction. If any one of them goes wrong, the current multiple looks less compelling than it appears.
Valuation
CVS trades at a discount to healthcare peers, and the discount is justified by the uncertainty, not by the asset quality of the underlying businesses. The question is whether the discount is already large enough to price in the risks.
The setup at $76.13:
- Market cap: ~$96.7B (1.271B shares outstanding x $76.13)
- Net debt: ~$55.2B ($63.7B total debt less $8.5B cash)
- Enterprise value: ~$151.9B
- 2025 adjusted operating income: $14.4B
- EV / adjusted operating income: ~10.5x
- P/E on 2025 adjusted EPS ($6.75): 11.3x
- P/E on 2026 guided adjusted EPS midpoint ($7.10): 10.7x
For context, UnitedHealth Group trades at roughly 16-17x forward earnings in a normal environment, and Elevance Health at 12-13x. CVS at 11x reflects the market pricing in persistent uncertainty around Aetna’s recovery, the debt load, and the impairment risk.
Method 1: P/E on Normalized Earnings
The key variable is what Aetna’s adjusted operating income normalizes to. In 2023 Aetna earned $5.6B. The PBM has been stable at $7.1-7.3B. The pharmacy segment has recovered to $6.0B. Corporate overhead runs about $1.7B negative. If you assume Aetna recovers toward target margins and everything else holds roughly steady, the normalized earnings picture looks like this:
| Scenario | Aetna AOI | Total AOI | Interest | Pre-tax | Adj. EPS (est.) | P/E Applied | Price Target |
|---|---|---|---|---|---|---|---|
| Bear | $1.5B | ~$12.2B | ($3.2B) | ~$9.0B | ~$5.50 | 9x | ~$49 |
| Base | $3.5B | ~$14.2B | ($3.1B) | ~$11.1B | ~$7.50 | 11x | ~$82 |
| Bull | $5.0B | ~$15.7B | ($3.0B) | ~$12.7B | ~$9.00 | 13x | ~$117 |
Assumptions: ~1.27B shares, ~19% effective tax rate, interest declining modestly as debt is paid down. Corporate overhead held at 2025 levels.
Method 2: FCF Yield
At $76.13 and 1.271B shares, CVS has a market cap of ~$96.7B. FCF in 2025 was $7.8B, but management guided 2026 OCF to at least $9B with capex likely similar to 2025. At $6.2-7.0B of estimated 2026 FCF, the FCF yield is roughly 6.4-7.2%. For a company with investment-grade credit, a large dividend, and potential earnings recovery, that is an attractive yield if the recovery thesis holds. The risk is that Aetna disappoints again and FCF compresses back toward 2024 levels, at which point the yield looks less compelling.
Method 3: Sum of the Parts
The integration thesis is the central debate with CVS. An SOTP analysis sidesteps that debate by asking a simpler question: what would each business be worth if it were a standalone company, and does the sum exceed the current enterprise value?
| Segment | Normalized AOI | Peer Multiple | Implied Value |
|---|---|---|---|
| Health Services (PBM) | ~$7.5B | 8-10x | $60-75B |
| Health Care Benefits (Aetna) | ~$4-5B | 10-12x | $40-60B |
| Pharmacy & Consumer Wellness | ~$6.0B | 6-8x | $36-48B |
| Gross Asset Value | $136-183B | ||
| Less: Net Debt | ($55.2B) | ||
| Equity Value | $81-128B | ||
| Per Share (1.271B shares) | $64-$101 |
A few notes on the assumptions:
- PBM normalized AOI assumes the delivery businesses are stripped out and the PBM alone runs at roughly $7.5B. The 8-10x multiple reflects Cigna’s Evernorth as the closest public comparable; PBMs trade at a discount to insurers due to political risk.
- Aetna normalized AOI uses $4-5B, below the 2023 peak of $5.6B but above the 2025 recovery level of $2.94B. The 10-12x multiple reflects Elevance Health as the primary comparable; Humana is too distressed to use as a benchmark right now.
- Pharmacy uses the $6.0B reported 2025 AOI with a 6-8x multiple. There is no clean public comp – Walgreens is in distress – so the multiple reflects a discount to the PBM and insurer businesses due to secular front-store pressure and reimbursement risk.
- Net debt is $63.7B total debt less $8.5B cash.
The SOTP bear case of ~$64/share implies the stock is slightly overvalued today if Aetna stays near current profitability levels. The base case of ~$78/share is roughly in line with the current price, suggesting the market is giving CVS credit for a partial Aetna recovery but not much more. The bull case of ~$101/share requires Aetna returning toward peak margins and the PBM holding its current earnings power – which is the full recovery thesis.
The SOTP analysis also surfaces something worth noting: there is no visible integration premium in the current stock price. If anything, the market appears to be applying a conglomerate discount – valuing the sum of the parts at roughly what the stock trades for today, with no premium for the synergies CVS has spent $88 billion trying to create. That could mean the integration thesis has not yet been proven, or it could mean the market is wrong. Either way, it is the right question to be asking.
Triangulation
Three methods, three different starting points, and they land in a consistent range:
| Method | Bear | Base | Bull |
|---|---|---|---|
| P/E on Normalized EPS | ~$49 | ~$82 | ~$117 |
| FCF Yield | ~$55-65 | ~$76-82 | ~$90+ |
| Sum of the Parts | ~$64 | ~$78 | ~$101 |
The base cases cluster around $78-82, which is modestly above the current price of $76.13. That is not a compelling margin of safety – it suggests the stock is roughly fairly valued if the base case plays out. The bear cases cluster around $49-65, which is meaningful downside if Aetna stumbles again. The bull cases range from $101-117, which requires a full recovery that the market is not pricing in.
CVS is not obviously cheap or obviously expensive at $76.13. It is a recovery story that is partway through its recovery, priced as though the recovery is real but incomplete. Whether that is the right price depends almost entirely on what Aetna does in 2026 and 2027.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Q1 2026 earnings | First read on whether Aetna MBR recovery holds into 2026 | Late April 2026 |
| 2027 Medicare Advantage final rates | CMS final notice will confirm or worsen the flat-rate advance notice; directly impacts Aetna pricing | By April 6, 2026 |
| Oak Street footprint decisions | Scope of continued closures signals how far the original thesis missed | Ongoing 2026 |
| CMS Medicare Advantage audits | Audits for payment years 2018-2024 are in progress; adverse findings could require material repayments | Early 2026 |
| PBM legislative activity | Congressional action on PBM practices and state-level prohibitions on integrated ownership | Throughout 2026 |
| Debt reduction pace | Management has prioritized deleveraging; credit rating trajectory is a signal of financial health | Quarterly |
| GLP-1 reimbursement dynamics | Revenue growth in the pharmacy segment is materially driven by branded GLP-1 drugs; biosimilar entry timing matters | Ongoing |
| Tariff impact on drug costs | Administration policy on pharmaceutical imports could increase cost of goods sold across both the pharmacy and PBM businesses | Ongoing |
Sources:
- CVS Health 10-K filed February 10, 2026
- CVS Health Q4 2025 Earnings Call Transcript, February 11, 2026
Research and analysis conducted with AI assistance using SEC EDGAR filings and earnings call transcripts as primary sources.